Pancreatic Cancer Research

ResearcherUniversity of PittsburghActive in the last 2 years

Alessandro Paniccia

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-7047-1711; OpenAlex author ID A5041614892. Sources: OpenAlex.

Their work

Papers
59 (first author 5, last author 19)
Trials
0
Grants
0
Labs led
2
Collaborators
134
Papers, trials and grants by year

2014: 1 paper · 2015: 3 papers · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 12 papers · 2022: 6 papers · 2023: 7 papers · 2024: 4 papers · 2025: 8 papers · 2026: 13 papers

Papers 50 of 59

  1. Pretreatment CA19-9 Predicts Survival in Pancreatic Cancer With Optimal Response to Neoadjuvant Therapy. Last author DOI 10.1002/jso.70179↗
  2. Cigarette smoking drives earlier development of pancreatic adenocarcinoma among carriers of hereditary pancreatic cancer susceptibility genes. Co-author DOI 10.1016/j.pan.2026.05.004↗
  3. Restaging after neoadjuvant FOLFIRINOX for localized pancreatic cancer: a clinical calculator from the Trans-Atlantic Pancreatic Surgery consortium. Co-author DOI 10.1093/jnci/djag024↗
  4. Pancreatic Cancer Organoids Recapitulate Chemotherapy Response and Identify a Potent Cytotoxic T-Cell Population. Co-author DOI 10.1158/1078-0432.ccr-25-1110↗
  5. KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Association with Survival in Localized Pancreatic Adenocarcinoma. Last author DOI 10.1245/s10434-025-18633-7↗
  6. Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Last author DOI 10.1245/s10434-026-20413-w↗
  7. ASO Visual Abstract: Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis. Last author DOI 10.1245/s10434-026-20555-x↗
  8. ASO Author Reflections: Liquid Biopsy in Resected Pancreatic Ductal Adenocarcinoma-From Prognostic Association to Clinical Utility. Last author DOI 10.1245/s10434-026-20585-5↗
  9. Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancreatic Surgery Consorti… Co-author DOI 10.1245/s10434-026-20620-5↗
  10. ASO Visual Abstract: Evaluation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Localized Pancreatic Cancer: Trans-Atlantic Pancre… Co-author DOI 10.1245/s10434-026-20742-w↗
  11. Neoadjuvant Therapy for Localized Pancreatic Cancer. Co-author DOI 10.3390/cancers18061011↗
  12. A Biomarker Panel for the Detection of Pancreatic Cancer. Co-author DOI 10.3390/cancers18091397↗
  13. Pancreatoblastoma: A Descriptive and Comparative Analysis with Pancreatic Ductal Adenocarcinoma Using SEER Data. Co-author DOI 10.3390/cancers18162642↗
  14. Implications of an Isolated Positive Vascular Groove After Whipple for Pancreatic Adenocarcinoma: A Single Institution, Retrospective Analysis. Last author DOI 10.1002/jso.70052↗
  15. Optimizing Perioperative Management of Pancreatic Ductal Adenocarcinoma: Insights Into Modified FOLFIRINOX Relative Dose Intensity and CA 19-9 Dynamics. Last author DOI 10.1002/jso.70057↗
  16. Survival prediction for CA19-9 non-producers with resected pancreatic cancer. Last author DOI 10.1016/j.hpb.2025.05.007↗
  17. Oncologic Efficacy of Robotic Compared to Open Total Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1016/j.jss.2024.10.043↗
  18. Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical… Co-author DOI 10.1093/bjs/znaf011↗
  19. Multimodal Therapy May be Key to Improving Survival for Octogenarians Undergoing Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma: An American Mult… Co-author DOI 10.1245/s10434-025-16916-7↗
  20. ASO Author Reflections: Beyond CA19-9—Integrating Extracellular Vesicle (EV)–KRAS Dynamics into Neoadjuvant Therapy Assessment for Pancreatic Cancer Co-author DOI 10.1245/s10434-025-18770-z↗
  21. ASO Visual Abstract: KRAS Mutation Allele Frequency Dynamics in Plasma Extracellular Vesicles: Associations with Survival in Localized Pancreatic Adenocarcinoma Last author DOI 10.1245/s10434-025-18842-0↗
  22. Postoperative infectious complications worsen oncologic outcomes following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jso.27595↗
  23. Impact of Neoadjuvant Therapy on Oncological Outcomes of Patients With Distal Pancreatic Adenocarcinoma. Last author DOI 10.1002/jso.27856↗
  24. Improved Clinical Staging System for Localized Pancreatic Cancer Using the ABC Factors: A TAPS Consortium Study. Co-author DOI 10.1200/jco.23.01311↗
  25. Pancreatic Cancer Multidisciplinary Clinic is Associated with Improved Treatment and Elimination of Socioeconomic Disparities. Co-author DOI 10.1245/s10434-023-14609-7↗
  26. The use of angiotensin system inhibitors correlates with longer survival in resected pancreatic adenocarcinoma patients. Last author DOI 10.1016/j.hpb.2022.12.002↗
  27. No survival benefit with suboptimal CA19-9 response: defining effective neoadjuvant chemotherapy in resectable or borderline resectable pancreatic cancer. Last author DOI 10.1016/j.hpb.2023.01.016↗
  28. National adoption of neoadjuvant chemotherapy: paradigm shift in the treatment of pancreatic cancer. Co-author DOI 10.1016/j.hpb.2023.06.018↗
  29. Obesity Is Associated With Increased Risk for Adverse Postoperative Outcomes After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1016/j.jss.2022.11.050↗
  30. A Combined DNA/RNA-based Next-Generation Sequencing Platform to Improve the Classification of Pancreatic Cysts and Early Detection of Pancreatic Cancer Arising… Co-author DOI 10.1097/sla.0000000000005904↗
  31. Editorial on: Moving Beyond Anatomic Criteria for Resectability: Validation of the Anatomical and Biological Definitions of Borderline Resectable Pancreatic Ca… Co-author DOI 10.1245/s10434-023-13271-3↗
  32. Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer. Co-author DOI 10.6004/jnccn.2023.7070↗
  33. Adaptive Dynamic Therapy and Survivorship for Operable Pancreatic Cancer. Co-author DOI 10.1001/jamanetworkopen.2022.18355↗
  34. Response to "Prognostic factors in patients with pancreatic ductal adenocarcinoma with neoadjuvant treatment and pancreatectomy". First author DOI 10.1002/jso.26853↗
  35. Tumor Size Differences Between Preoperative Endoscopic Ultrasound and Postoperative Pathology for Neoadjuvant-Treated Pancreatic Ductal Adenocarcinoma Predict … Co-author DOI 10.1016/j.cgh.2020.11.041↗
  36. Advances in the Surgical Treatment of Pancreatic Cancer. First author DOI 10.1016/j.path.2022.05.003↗
  37. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium. Co-author DOI 10.1093/jnci/djac018↗
  38. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study. Co-author DOI 10.6004/jnccn.2022.7008↗
  39. Neoadjuvant therapy versus upfront surgery for early-stage left-sided pancreatic adenocarcinoma: A propensity-matched analysis from a national cohort of distal… Last author DOI 10.1002/jso.26267↗
  40. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma. Last author DOI 10.1002/jso.26510↗
  41. Medicaid expansion and the management of pancreatic cancer. Co-author DOI 10.1002/jso.26515↗
  42. Safety and oncologic efficacy of robotic compared to open pancreaticoduodenectomy after neoadjuvant chemotherapy for pancreatic cancer. Last author DOI 10.1007/s00464-020-07638-w↗
  43. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. Co-author DOI 10.1007/s11605-020-04870-6↗
  44. Perioperative and oncologic outcomes of open, laparoscopic, and robotic distal pancreatectomy for pancreatic adenocarcinoma. Last author DOI 10.1007/s13304-020-00927-y↗
  45. Baseline Plasma Inflammatory Profile Is Associated With Response to Neoadjuvant Chemotherapy in Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1097/cji.0000000000000370↗
  46. Outcomes of Neoadjuvant Chemotherapy Versus Chemoradiation in Localized Pancreatic Cancer: A Case-Control Matched Analysis. Co-author DOI 10.1245/s10434-020-09391-9↗
  47. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. Last author DOI 10.1245/s10434-020-09446-x↗
  48. ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy. First author DOI 10.1245/s10434-020-09487-2↗
  49. A Pancreatic Cancer Multidisciplinary Clinic Eliminates Socioeconomic Disparities in Treatment and Improves Survival. Co-author DOI 10.1245/s10434-021-09594-8↗
  50. Does neoadjuvant therapy improve survival in pancreatic adenocarcinoma? First author DOI 10.21037/hbsn-21-250↗

Closest collaborators

The 25 strongest of 134 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Amer H. Zureikat · 42 shared papers, 2020–2026 · strength 8.28
  2. Ibrahim Nassour · 19 shared papers, 2020–2026 · strength 3.52
  3. Sebastiaan Ceuppens · 10 shared papers, 2025–2026 · strength 2.87
  4. Asmita Chopra · 13 shared papers, 2021–2026 · strength 2.75
  5. Aatur Dilip Singhi · 15 shared papers, 2021–2026 · strength 2.73
  6. Bas Groot Koerkamp · 10 shared papers, 2019–2026 · strength 2.06
  7. Jiage Qian · 6 shared papers, 2025–2026 · strength 1.83
  8. Matthew H. G. Katz · 8 shared papers, 2019–2026 · strength 1.46
  9. Marc G. Besselink · 8 shared papers, 2019–2026 · strength 1.46
  10. Eileen Mary O'Reilly · 7 shared papers, 2022–2026 · strength 1.40
  11. Ching-Wei David Tzeng · 7 shared papers, 2022–2026 · strength 1.40
  12. Alice Chia-Chi Wei · 7 shared papers, 2022–2026 · strength 1.40
  13. Nathan Bahary · 11 shared papers, 2019–2023 · strength 1.36
  14. Samer S. AlMasri · 8 shared papers, 2021–2024 · strength 1.33
  15. Esther N. Dekker · 5 shared papers, 2024–2026 · strength 1.15
  16. Steven J. Hughes · 4 shared papers, 2023–2026 · strength 1.03
  17. Richard S. Hoehn · 7 shared papers, 2020–2024 · strength 1.00
  18. Brian A. Boone · 7 shared papers, 2019–2026 · strength 0.95
  19. Caroline J. Rieser · 6 shared papers, 2021–2025 · strength 0.92
  20. Hussein H. Khachfe · 5 shared papers, 2023–2024 · strength 0.90
  21. Melissa Ellen Hogg · 6 shared papers, 2021–2026 · strength 0.87
  22. Herbert J. Zeh · 6 shared papers, 2021–2026 · strength 0.87
  23. Laura R. Prakash · 5 shared papers, 2022–2026 · strength 0.86
  24. Jordan A. McKean · 3 shared papers, 2025–2026 · strength 0.85
  25. Mohamed A. Adam · 5 shared papers, 2020–2021 · strength 0.82

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.